Literature DB >> 1684309

The current unsatisfactory state of relapse prevention in schizophrenic psychoses--suggestions for improvement.

W Kissling1.   

Abstract

The current state of relapse prevention in schizophrenic psychoses is very unsatisfactory. Although in the form of neuroleptics a very efficient means of relapse prevention has been available for almost 40 years, approximately 50% of the schizophrenic patients still suffer a relapse within the first year after their most recent episode. Seventy percent of the hospitalized schizophrenic patients are readmissions, and the noncompliance rate for neuroleptic relapse prevention is 75%. An important factor contributing to these high rates of noncompliance and relapse seems to be the fact that, 40 years after the introduction of neuroleptics, there is still no consensus on how these drugs are to be used in relapse prevention. An inquiry among Austrian and German psychiatrists revealed unacceptably high discrepancies concerning their recommendations for indication and duration of neuroleptic relapse prevention. To overcome this unsatisfactory situation, an international consensus meeting on guidelines for neuroleptic relapse prevention was organized by the author in April 1989. Precise guidelines on indication, duration, and dosage of neuroleptic for relapse prevention that resulted from that meeting are presented.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1684309

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  10 in total

1.  What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?

Authors:  Christoph U Correll; Jose M Rubio; John M Kane
Journal:  World Psychiatry       Date:  2018-06       Impact factor: 49.548

Review 2.  [Long-term treatment of schizophrenia spectrum disorders: focus on pharmacotherapy].

Authors:  L Deutschenbaur; M Lambert; M Walter; D Naber; C G Huber
Journal:  Nervenarzt       Date:  2014-03       Impact factor: 1.214

3.  Assessment and treatment selection for "revolving door" inpatients with schizophrenia.

Authors:  P Weiden; W Glazer
Journal:  Psychiatr Q       Date:  1997

Review 4.  Ziprasidone: a review of its use in schizophrenia and schizoaffective disorder.

Authors:  Nishan S Gunasekara; Caroline M Spencer; Gillian M Keating
Journal:  Drugs       Date:  2002       Impact factor: 9.546

5.  Pharmacologic treatment of first-episode schizophrenia: a review of the literature.

Authors:  Shibu P Thomas; Harpal Sing Nandhra; Swaran P Singh
Journal:  Prim Care Companion CNS Disord       Date:  2012-01-05

6.  Treatment Effect of Long-Term Antipsychotics on Default-Mode Network Dysfunction in Drug-Naïve Patients With First-Episode Schizophrenia: A Longitudinal Study.

Authors:  Mengjie Deng; Zhening Liu; Yanyu Shen; Hengyi Cao; Manqi Zhang; Chang Xi; Wen Zhang; Wenjian Tan; Jinqiang Zhang; Eric Chen; Edwin Lee; Weidan Pu
Journal:  Front Pharmacol       Date:  2022-05-20       Impact factor: 5.988

Review 7.  Depot antipsychotic drugs. Place in therapy.

Authors:  J M Davis; L Matalon; M D Watanabe; L Blake; L ] Metalon L [corrected to Matalon
Journal:  Drugs       Date:  1994-05       Impact factor: 9.546

8.  Cariprazine on Psychosis: Beyond Schizophrenia - A Case Series.

Authors:  Miguel Bajouco; David Mota
Journal:  Neuropsychiatr Dis Treat       Date:  2022-07-05       Impact factor: 2.989

9.  The Amsterdam Studies of Acute Psychiatry I (ASAP-I); a prospective cohort study of determinants and outcome of coercive versus voluntary treatment interventions in a metropolitan area.

Authors:  Louk van der Post; Robert Schoevers; Vincent Koppelmans; Irene Visch; Clemens Bernardt; Niels Mulder; Aartjan Beekman; Lieuwe de Haan; Jack Dekker
Journal:  BMC Psychiatry       Date:  2008-05-14       Impact factor: 3.630

10.  Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia.

Authors:  Gunnar Morken; Jan H Widen; Rolf W Grawe
Journal:  BMC Psychiatry       Date:  2008-04-30       Impact factor: 3.630

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.